Wegovy® Injection
An FDA‑approved once‑weekly GLP‑1 injection for chronic weight management — with proven cardiovascular benefits and an average 15% weight loss in clinical trials.
Semaglutide Injection — Once‑Weekly GLP‑1 Therapy
FlexTouch® PenProven Weekly Injection
The Wegovy® injection is a pre‑filled, disposable FlexTouch® pen that delivers semaglutide once weekly. Backed by the landmark STEP and SELECT clinical trial programs, it's one of the most studied weight loss medications available.
- GLP‑1 receptor agonist (semaglutide)
- Average 15% body weight loss in clinical trials
- FDA‑approved for cardiovascular risk reduction
- Once‑weekly pre‑filled pen
- Gradual dose escalation (0.25 mg – 2.4 mg)
- Manufactured by Novo Nordisk
Why Choose the Wegovy® Injection?
A proven, well‑established GLP‑1 therapy backed by extensive clinical research and real‑world results.
Average 15% Weight Loss
In the STEP clinical trial program, patients on Wegovy® lost an average of 15% of their body weight over 68 weeks, with significant improvements starting within the first few months of treatment.
Cardiovascular Benefits
Wegovy® is the first and only weight loss medication with FDA approval for reducing the risk of major cardiovascular events in adults with obesity and established heart disease.
Simple Once‑Weekly Pen
Administered using a pre‑filled, disposable FlexTouch® pen. One quick subcutaneous injection per week — in the abdomen, thigh, or upper arm. No mixing or preparation needed.
How Wegovy® Injection Works
A targeted GLP‑1 therapy that works with your body's natural appetite regulation system.
Appetite Regulation
Wegovy® activates GLP‑1 receptors in the brain that control hunger and satiety. This helps you feel full and satisfied with smaller portions, naturally reducing your calorie intake.
Reduced Cravings
By mimicking the natural GLP‑1 hormone, Wegovy® reduces food cravings — especially for high‑calorie foods — making it easier to stick to a healthy nutrition plan.
Slower Gastric Emptying
The injection slows the rate at which food leaves your stomach, promoting longer‑lasting fullness after each meal and helping you naturally eat less throughout the day.
Cardiovascular Protection
In the SELECT trial, Wegovy® reduced the risk of major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease — a landmark finding for weight loss medications.
Dosing & Administration
A straightforward once‑weekly injection with a gradual dose escalation schedule.
FlexTouch® Pen
The Wegovy® pen is a pre‑filled, disposable auto‑injector. Select your injection site, press the pen to your skin, and press the button. The fine needle makes the injection quick and virtually painless.
Dose Escalation Schedule
Treatment begins at 0.25 mg weekly and increases every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose. This 16‑20 week escalation helps minimize gastrointestinal side effects.
Flexible Weekly Schedule
Inject on the same day each week, at any time of day, with or without meals. If you need to change your injection day, simply ensure at least 2 days between doses.
Storage
Store unused pens in the refrigerator (36°F–46°F). Once in use, a pen can be kept at room temperature or refrigerated for up to 28 days. Do not freeze.
Safety & Side Effects
Backed by extensive clinical trials and ongoing physician monitoring at every step.
Common Side Effects
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate and tend to improve during the dose escalation period as your body adjusts.
Important Safety Information
Wegovy® is not recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Our comprehensive evaluation screens for all contraindications before treatment begins.
Wegovy® Injection FAQs
Common questions about the Wegovy® (semaglutide) weekly injection.
Wegovy® (semaglutide) targets GLP‑1 receptors, while Zepbound® (tirzepatide) targets both GIP and GLP‑1 receptors. Wegovy® has the unique advantage of FDA approval for cardiovascular risk reduction. Both are effective — our physicians will help you choose the best fit.
Both deliver semaglutide and are effective for weight loss. The weekly injection is well‑established with extensive clinical data. The daily pill offers a needle‑free option. Our physicians will discuss both options during your consultation.
Most patients report minimal discomfort. The FlexTouch® pen uses a fine, short needle, and the injection takes just a few seconds. Our team will teach you the proper technique at your first visit.
Most patients notice reduced appetite within the first 2‑4 weeks. Meaningful weight loss typically begins within the first 1‑2 months, with results accelerating as the dose increases. The full maintenance dose is reached around week 16‑20.
Treatment duration varies by individual. Many patients benefit from 12 months or longer of treatment. Our program combines medication with nutrition coaching and lifestyle support for sustained long‑term results.
Coverage is expanding as more insurance plans recognize GLP‑1 medications for weight loss. Our team can assist with prior authorization, manufacturer savings cards, and self‑pay pricing to help make treatment accessible.
Ready to Start Wegovy® Injections?
Schedule a free consultation to find out if the Wegovy® injection is the right choice for your weight loss goals.